Final NICE guidance rejects Novartis's higher dose Glivec for GIST
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has today published final guidance rejecting Novartis's Glivec (imatinib) in higher doses for patients with unresectable and/or metastatic gastrointestinal stromal tumours (GIST) after standard doses have stopped working. According to the institute, there is not enough evidence to justify use of 600 or 800mg/day.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.